



A



B



Supplemental Figure 1: Change of GE/ml (total amount of circulating DNA) [A] or cmDNA (circulating DNA of tumor origin) [B], between under treatment and baseline timepoint. Stratification of the patients is performed according to the need for dose reduction (Yes/No). While a non-significant increase in total cfDNA amount (GE/ml) change in patients who required a dose reduction is observed the cmDNA (expected to be solely of tumor origin) remained similar between the two subgroups.